Pub Date : 2024-09-01DOI: 10.1016/j.nefro.2024.02.001
{"title":"Niveles de creatinina elevados y cistatina normales en un paciente que recibe ribociclib","authors":"","doi":"10.1016/j.nefro.2024.02.001","DOIUrl":"10.1016/j.nefro.2024.02.001","url":null,"abstract":"","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"44 5","pages":"Pages 762-764"},"PeriodicalIF":2.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0211699524000079/pdfft?md5=51cb0d6e5e0a65114a717376eb818cf8&pid=1-s2.0-S0211699524000079-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139878831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-01DOI: 10.1016/j.nefro.2024.05.007
{"title":"La implantación de la cardionefrología en España es una urgencia sanitaria","authors":"","doi":"10.1016/j.nefro.2024.05.007","DOIUrl":"10.1016/j.nefro.2024.05.007","url":null,"abstract":"","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"44 5","pages":"Pages 619-622"},"PeriodicalIF":2.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0211699524000420/pdfft?md5=9650813087a2833b2f01d6a147f82ece&pid=1-s2.0-S0211699524000420-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141142376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-01DOI: 10.1016/j.nefro.2024.05.002
Valerie A. Luyckx , Katherine R. Tuttle , Dina Abdellatif , Ricardo Correa-Rotter , Winston W.S. Fung , Agnès Haris , Li-Li Hsiao , Makram Khalife , Latha A. Kumaraswami , Fiona Loud , Vasundhara Raghavan , Stefanos Roumeliotis , Marianella Sierra , Ifeoma Ulasi , Bill Wang , Siu-Fai Lui , Vassilios Liakopoulos , Alessandro Balducci , for the World Kidney Day Joint Steering Committee
Historically, it takes an average of 17 years to move new treatments from clinical evidence to daily practice. Given the highly effective treatments now available to prevent or delay kidney disease onset and progression, this is far too long. The time is now to narrow the gap between what we know and what we do. Clear guidelines exist for the prevention and management of common risk factors for kidney disease, such as hypertension and diabetes, but only a fraction of people with these conditions worldwide are diagnosed, and even fewer are treated to target. Similarly, the vast majority of people living with kidney disease are unaware of their condition, because in the early stages it is often silent. Even among patients who have been diagnosed, many do not receive appropriate treatment for kidney disease. Considering the serious consequences of kidney disease progression, kidney failure, or death, it is imperative that treatments are initiated early and appropriately. Opportunities to diagnose and treat kidney disease early must be maximized beginning at the primary care level. Many systematic barriers exist, ranging from patient to clinician to health systems to societal factors. To preserve and improve kidney health for everyone everywhere, each of these barriers must be acknowledged so that sustainable solutions are developed and implemented without further delay.
{"title":"Mind the gap in kidney care: Translating what we know into what we do","authors":"Valerie A. Luyckx , Katherine R. Tuttle , Dina Abdellatif , Ricardo Correa-Rotter , Winston W.S. Fung , Agnès Haris , Li-Li Hsiao , Makram Khalife , Latha A. Kumaraswami , Fiona Loud , Vasundhara Raghavan , Stefanos Roumeliotis , Marianella Sierra , Ifeoma Ulasi , Bill Wang , Siu-Fai Lui , Vassilios Liakopoulos , Alessandro Balducci , for the World Kidney Day Joint Steering Committee","doi":"10.1016/j.nefro.2024.05.002","DOIUrl":"10.1016/j.nefro.2024.05.002","url":null,"abstract":"<div><p>Historically, it takes an average of 17 years to move new treatments from clinical evidence to daily practice. Given the highly effective treatments now available to prevent or delay kidney disease onset and progression, this is far too long. The time is now to narrow the gap between what we know and what we do. Clear guidelines exist for the prevention and management of common risk factors for kidney disease, such as hypertension and diabetes, but only a fraction of people with these conditions worldwide are diagnosed, and even fewer are treated to target. Similarly, the vast majority of people living with kidney disease are unaware of their condition, because in the early stages it is often silent. Even among patients who have been diagnosed, many do not receive appropriate treatment for kidney disease. Considering the serious consequences of kidney disease progression, kidney failure, or death, it is imperative that treatments are initiated early and appropriately. Opportunities to diagnose and treat kidney disease early must be maximized beginning at the primary care level. Many systematic barriers exist, ranging from patient to clinician to health systems to societal factors. To preserve and improve kidney health for everyone everywhere, each of these barriers must be acknowledged so that sustainable solutions are developed and implemented without further delay.</p></div>","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"44 5","pages":"Pages 731-742"},"PeriodicalIF":2.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0211699524000377/pdfft?md5=694bbd257e5ed54a9b863696d5a43532&pid=1-s2.0-S0211699524000377-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142163955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-01DOI: 10.1016/j.nefro.2022.12.010
{"title":"Pielonefritis aguda en paciente trasplantado renal secundaria a infección por Delftia acidovorans: a propósito de un caso","authors":"","doi":"10.1016/j.nefro.2022.12.010","DOIUrl":"10.1016/j.nefro.2022.12.010","url":null,"abstract":"","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"44 4","pages":"Pages 593-594"},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0211699522002053/pdfft?md5=73ad6f2fcbe66aa365b982ee7c24d505&pid=1-s2.0-S0211699522002053-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46964280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-01DOI: 10.1016/j.nefro.2023.01.001
{"title":"Targeting colonic BK channels: A novel therapeutic strategy against hyperkalemia in chronic kidney disease","authors":"","doi":"10.1016/j.nefro.2023.01.001","DOIUrl":"10.1016/j.nefro.2023.01.001","url":null,"abstract":"","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"44 4","pages":"Pages 594-596"},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0211699523000012/pdfft?md5=26c511d85510be6f636f623de20bb35e&pid=1-s2.0-S0211699523000012-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"55187953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-01DOI: 10.1016/j.nefro.2023.04.002
{"title":"Karyomegalic nephropathy – Letter to the Editor","authors":"","doi":"10.1016/j.nefro.2023.04.002","DOIUrl":"10.1016/j.nefro.2023.04.002","url":null,"abstract":"","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"44 4","pages":"Pages 604-605"},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0211699523000632/pdfft?md5=3b167a809edef0839bbc18df4149678a&pid=1-s2.0-S0211699523000632-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"55187982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-01DOI: 10.1016/j.nefro.2023.09.003
{"title":"Individualización y desafíos para la hemodiálisis de la próxima década","authors":"","doi":"10.1016/j.nefro.2023.09.003","DOIUrl":"10.1016/j.nefro.2023.09.003","url":null,"abstract":"","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"44 4","pages":"Pages 459-464"},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0211699523001443/pdfft?md5=dd7a60329517676941acadf6ca6099f0&pid=1-s2.0-S0211699523001443-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135298865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-01DOI: 10.1016/j.nefro.2023.11.005
Busra Candan , Ilter Ilhan , Emine Sarman , Murat Sevimli
Introduction
Acute kidney injury (AKI) is a serious pathology that progress with dysfunction of regulating blood pressure and fluid balance, concentrating urine due to decrement of aquaporin-1 (AQP) levels during the inflammation process. Irbesartan (IRN), angiotensin receptor blocker, is widely used in the treatment of hypertension, which also has anti-inflammatory, antioxidant and anti-apoptotic properties. The aim of this study is to investigate the protective effects of IRN in lipopolysaccharide (LPS)-induced kidney injury.
Material and methods
Twenty-four rats divided into three groups as control, LPS and LPS + IRN group. After 6 h of LPS administration, rats were sacrificed. Blood samples and half of the kidney tissues were collected for biochemical analysis and remaining tissues were taken for histopathological and immunohistochemical analysis.
Results
In the LPS group, glomerular congestion and shrinkage, degeneration of distal tubules, mononuclear cell infiltration, cellular debris and intense proteinous accumulation in the tubules, increased expressions of Cas-3, nuclear factor kappa beta-p65 (NF-kB p65), levels of creatinin, TOS, OSI and decreased levels of TAS, AQP-1 were found significantly. IRN treatment reversed all these parameters. IRN's restorated AQP-1 levels by its anti-inflammatory, antioxidant and anti-apoptotic effects due to inhibiting NF-kB expression.
Conclusion
This study suggests that IRN can be used in conditions affecting the kidneys such as AKI. Further studies needed for detailed molecular investigation of IRN at different doses and durations.
{"title":"Irbesartan restored aquaporin-1 levels via inhibition of NF-kB expression in acute kidney injury model","authors":"Busra Candan , Ilter Ilhan , Emine Sarman , Murat Sevimli","doi":"10.1016/j.nefro.2023.11.005","DOIUrl":"10.1016/j.nefro.2023.11.005","url":null,"abstract":"<div><h3>Introduction</h3><p>Acute kidney injury (AKI) is a serious pathology that progress with dysfunction of regulating blood pressure and fluid balance, concentrating urine due to decrement of aquaporin-1 (AQP) levels during the inflammation process. Irbesartan (IRN), angiotensin receptor blocker, is widely used in the treatment of hypertension, which also has anti-inflammatory, antioxidant and anti-apoptotic properties. The aim of this study is to investigate the protective effects of IRN in lipopolysaccharide (LPS)-induced kidney injury.</p></div><div><h3>Material and methods</h3><p>Twenty-four rats divided into three groups as control, LPS and LPS<!--> <!-->+<!--> <!-->IRN group. After 6<!--> <!-->h of LPS administration, rats were sacrificed. Blood samples and half of the kidney tissues were collected for biochemical analysis and remaining tissues were taken for histopathological and immunohistochemical analysis.</p></div><div><h3>Results</h3><p>In the LPS group, glomerular congestion and shrinkage, degeneration of distal tubules, mononuclear cell infiltration, cellular debris and intense proteinous accumulation in the tubules, increased expressions of Cas-3, nuclear factor kappa beta-p65 (NF-kB p65), levels of creatinin, TOS, OSI and decreased levels of TAS, AQP-1 were found significantly. IRN treatment reversed all these parameters. IRN's restorated AQP-1 levels by its anti-inflammatory, antioxidant and anti-apoptotic effects due to inhibiting NF-kB expression.</p></div><div><h3>Conclusion</h3><p>This study suggests that IRN can be used in conditions affecting the kidneys such as AKI. Further studies needed for detailed molecular investigation of IRN at different doses and durations.</p></div>","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"44 4","pages":"Pages 540-548"},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0211699523001765/pdfft?md5=1a73f917f523cbbdc48971de3c1b4b06&pid=1-s2.0-S0211699523001765-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141622893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-01DOI: 10.1016/j.nefro.2023.02.007
{"title":"Nefropatía IgA tras tratamiento prolongado con infliximab por enfermedad de Crohn, a propósito de dos casos","authors":"","doi":"10.1016/j.nefro.2023.02.007","DOIUrl":"10.1016/j.nefro.2023.02.007","url":null,"abstract":"","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"44 4","pages":"Pages 599-601"},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0211699523000346/pdfft?md5=460d082aa65d39675f6b0cefc16b4077&pid=1-s2.0-S0211699523000346-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46354041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号